Raymond Dingledine PhD
- Department of Pharmacology & Chemical Biology
Adjunct Professor
- (404) 727-5982
- rdingle@emory.edu
-
Emory University School of Medicine
Pharmacology
1510 Clifton Rd. , Room 5001
Overview
Glutamate receptors mediate the vast majority of excitatory synaptic transmission in the brain. A major research effort is focused on regulation of glutamate receptor-mediated synaptic transmission in the brain by the co-activation of selected G-protein coupled receptors. A second research emphasis involves the use of microarray and associated technologies to identify novel targets and pathways involved in the basic cellular and molecular mechanisms of epilepsy. These research interests converge and have highlighted a role for cyclooxygenase-2 (COX2) signaling pathways in the cognitive deficits, impaired synaptic inhibition, and eurodegeneration caused by seizures. We are currently exploring the consequences of conditional COX2 knockouts and are seeking the prostaglandin receptors responsible for each of these effects; we are employing a chemical biology approach to develop novel small molecule modulators of these receptors in an effort to interrupt the development of epilepsy. As a whole our work integrates information from a variety of experimental strategies to contribute to a better understanding of epilepsy, with broad implications for other brain disorders including stroke and schizophrenia.
Academic Appointment
- Professor and Chairman, Dept. Pharmacology, Emory University School of Medicine
- Research Associate, Dept. of Physiology, Duke University
Education
Degrees
- PhD from Stanford University
- BS from Michigan State University
Research
Publications
-
Disease modification upon 2 weeks of tofacitinib treatment in a mouse model of chronic epilepsy.
Sci Transl Med Volume: 17 Page(s): eadt0527
03/19/2025 Authors: Hoffman OR; Koehler JL; Espina JEC; Patterson AM; Gohar ES; Coleman EM; Schoenike BA; Espinosa-Garcia C; Paredes F; Varvel NH -
Disease modification upon brief exposure to tofacitinib during chronic epilepsy.
bioRxiv
11/21/2024 Authors: Hoffman OR; Koehler JL; Espina JEC; Patterson AM; Gohar ES; Coleman E; Schoenike BA; Espinosa-Garcia C; Paredes F; Varvel NH -
Memory loss and aberrant neurogenesis in mice exposed to patient anti-N-methyl-d-aspartate receptor antibodies.
Exp Neurol Volume: 378 Page(s): 114838
08/01/2024 Authors: Taraschenko O; Fox HS; Heliso P; Al-Saleem F; Dessain S; Kim W-Y; Samuelson MM; Dingledine R -
MyD88-mediated signaling is critical for the generation of seizure responses and cognitive impairment in a model of anti-N-methyl-D-aspartate receptor encephalitis.
Epilepsia Volume: 65 Page(s): 1475 - 1487
05/01/2024 Authors: Taraschenko O; Fox HS; Eldridge E; Heliso P; Al-Saleem F; Dessain S; Casale G; Willcockson G; Anderson K; Wang W -
Epilepsy insights revealed by intravital functional optical imaging.
Front Neurol Volume: 15 Page(s): 1465232
01/01/2024 Authors: Stern MA; Dingledine R; Gross RE; Berglund K -
One Ring to Bind Them: The Annulus of GABAergic Inhibitory Restraint Fades at Seizure Emergence.
Epilepsy Curr Volume: 24 Page(s): 53 - 55
01/01/2024 Authors: Stern MA; Dingledine R -
Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor.
Clin Pharmacol Drug Dev Volume: 12 Page(s): 706 - 717
07/01/2023 Authors: Zaczek R; Traynelis SF; Dingledine R; Koszalka GW; Laskowitz DT -
Pharmacological inhibition of the inflammatory receptor CCR2 relieves the early deleterious consequences of status epilepticus.
Sci Rep Volume: 13 Page(s): 5651
04/06/2023 Authors: Alemn-Ruiz C; Wang W; Dingledine R; Varvel NH -
Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model.
ACS Chem Neurosci Volume: 14 Page(s): 917 - 935
03/01/2023 Authors: Harris LD; Regan MC; Myers SJ; Nocilla KA; Akins NS; Tahirovic YA; Wilson LJ; Dingledine R; Furukawa H; Traynelis SF -
Preclinical development of an EP2 antagonist for post-seizure cognitive deficits.
Neuropharmacology Volume: 224 Page(s): 109356
02/15/2023 Authors: Varvel NH; Amaradhi R; Espinosa-Garcia C; Duddy S; Franklin R; Banik A; Alemn-Ruiz C; Blackmer-Raynolds L; Wang W; Honore T